Interestingly, they found that the effects of this nutrient aren't direct, but seem to be mediated by how it's metabolized by gut bacteria
The particularly exciting thing about this class of diabetes medications is that, in contrast to many currently available diabetes drugs that address downstream effects, these medications target the root cause of diabetes
The trial Evaluating Liraglutide in Alzheimers Disease (ELAD) recently completed a 12-month phase 2b clinical trial of liraglutide in 204 AD patients, awaiting publication [60]
Should it still be the first-line agent, or have newer drug classes like GLP1 receptor agonists and SGLT2 inhibitors earned Read More GLP1s and Liver Disease: Rethinking MASLD Care Beyond Obesity and A1C Jan 26, 2026 Articles, Diabetes, Featured, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 2,767 views Nonalcoholic steatohepatitis (NASH) and metabolic dysfunctionassociated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide
Current research is still in its early stages, and more studies are required to fully assess its safety and long-term effects
